Published on
The $200,000 award will fund research to develop a novel therapeutic that ignites the immune system and could act as a stand-alone treatment, as well as boost the effectiveness of existing immunotherapies.
Published on
CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.
Published on
Families make long journeys — and even relocate — so their children can receive specialized treatment at CHOP.
Published on
Stephan Grupp, MD, PhD, Chief of the Cell Therapy and Transplant Section in the Division of Oncology, has been elected into the National Academy of Medicine (NAM).
Published on
The National Academy of Medicine elects two global leaders in cellular and gene therapy from Children’s Hospital of Philadelphia.
Published on
Trials of more game-changing cell therapies for pediatric cancer and other diseases are underway or on the horizon at Children's Hospital of Philadelphia.
Published on
An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.
Published on
CHOP researchers analyze how some cancer cells resist a groundbreaking cellular therapy, and have found clues to overcoming that resistance.
Published on
The grand opening of CHOP’s new Clinical Manufacturing Facility highlights its role in manufacturing tools for 21st century precision medicine, to bring innovative treatments to patients.
Published on
Children’s Hospital of Philadelphia was recognized specifically for significant contributions to the development of a new treatment for a certain pediatric leukemia.